Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 19/20 | 0.75 |
| ▸ | RXRB | P28702 | 13/20 | 0.75 |
| ▸ | RXRG | P48443 | 13/20 | 0.75 |
| ▸ | RARB | P10826 | 4/20 | 0.52 |
| ▸ | RARG | P13631 | 4/20 | 0.52 |
| ▸ | RARA | P10276 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17049085 | 0.86 | RXRA (1.00) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL6087579 | 0.84 | RXRA (0.53) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL8115665 | 0.83 | RXRA (0.53) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL501775 | 0.82 | RXRA (0.52) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL5179608 | 0.82 | RXRA (0.76) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL29463956 | 0.79 | RXRA (1.00) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL17049055 | 0.74 | RXRA (0.77) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL502086 | 0.73 | RXRA (1.00) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL20411354 | 0.73 | RXRA (0.76) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL6239533 | 0.73 | RXRA (0.62) | RXRARXRBRXRGRARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291492-A1 | METHOD FOR FORMING ORGAN | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2009-11-26 | — | — | US | claimed |
| US-20070161105-A1 | Method of forming organ | REASEARCH FOUNDATION ITSUU LABORATORY (JP) | 2007-07-12 | — | — | US | claimed |
| EP-1612264-A1 | ORGAN-FORMING METHOD | Research Foundation Itsuu Laboratory (JP) | 2006-01-04 | — | — | EP | claimed |
| US-20240277714-A1 | USE OF SOS1 INHIBITORS WITH RAS INHIBITORS TO TREAT CANCERS | Revolution Medicines, Inc. | 2024-08-22 | — | — | US | disclosed |
| US-20240108630-A1 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. | 2024-04-04 | — | — | US | disclosed |
| US-20220235134-A1 | ANTI-B7-H3 ANTIBODIES | SINGLE CELL TECHNOLOGY, INC. (US) | 2022-07-28 | — | — | US | disclosed |
| EP-3976660-A1 | ANTI-B7-H3 ANTIBODIES | Single Cell Technology, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20070161105-A1 | Method of forming organ | REASEARCH FOUNDATION ITSUU LABORATORY (JP) | 2007-07-12 | — | — | US | disclosed |
| EP-1612264-A1 | ORGAN-FORMING METHOD | Research Foundation Itsuu Laboratory (JP) | 2006-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277714-A1 | USE OF SOS1 INHIBITORS WITH RAS INHIBITORS TO TREAT CANCERS | SOS1, HRAS, KRAS | RXRA 2753/4885RXRB 2464/4885RXRG 2947/4885 |
| US-20240108630-A1 | METHODS FOR INHIBITING RAS | KRAS, HRAS, NRAS | RXRA 3472/4885RXRB 3237/4885RXRG 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.